参考文献/References:
[1]D?hner H,Wei AH,L?wenberg B.Towards precision medicine for AML[J].Nat Rev Clin Oncol,2021,18(9):577-590.[2]Ive YA,Hills RK,Simpson MA,et al.Assessment of Minimal Residual Disease in Standard-Risk AML[J].N Engl J Med,2016,374(5):422-433.[3]Vanneman M,Dranoff G.Combining immunotherapy and targeted therapies in cancer treatment[J].Nat Rev Cancer,2012,12(4):237-251.[4]Junttila MR,de Sauvage FJ.Influence of tumour micro-environment heterogeneity on therapeutic response[J].Nature,2013,501(7467):346-354.[5]Mao X,Xu J,Wang W,et al.Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives[J].Mol Cancer,2021,20(1):131.[6]Yang Q,Guo N,Zhou Y,et al.The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy[J].Acta Pharm Sin B,2020,10(11):2156-2170.[7]Wang Y,Yu J,Luo Z,et al.Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy[J].Adv Mater,2021,33(39):e2103497.[8]Wang J,Xu L,Xiang Z,et al.Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206(+) M2-like macrophage polarization[J].Cell Death Dis,2020,11(2):136.[9]Vasconcelos DP,Costa M,Amaral IF,et al.Modulation of the inflammatory response to chitosan through M2 macrophage polarization using pro-resolution mediators[J].Biomaterials,2015,37:116-123.[10]Tan J,Fan W,Liu T,et al.TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma[J].J Hepatol,2023,79(1):126-140.[11]Kemp SB,Carpenter ES,Steele NG,et al.Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1[J].Cancer Res,2021,81(16):4305-4318.[12]Xiang X,Wang J,Lu D,et al.Targeting tumor-associated macrophages to synergize tumor immunotherapy[J].Signal Transduct Target Ther,2021,6(1):75.[13]Xia Y,Rao L,Yao H,et al.Engineering Macrophages for Cancer Immunotherapy and Drug Delivery[J].Adv Mater,2020, 32(40):e2002054.[14]Li C,Xu X,Wei S,et al.Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer[J].J Immunother Cancer,2021,9(1):e001341.[15]Kumari N,Choi SH.Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies[J].J Exp Clin Cancer Res,2022,41(1):68.[16]Bai R,Li Y,Jian L,et al.The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies[J].Mol Cancer,2022,21(1):177.[17]Ngambenjawong C,Gustafson HH,Pun SH.Progress in tumor-associated macrophage (TAM)-targeted therapeutics[J].Adv Drug Deliv Rev,2017,114:206-221.[18]Yang H,Zhang Q,Xu M,et al.CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis[J].Mol Cancer,2020,19(1):41.[19]Geraldo LH,Xu Y,Jacob L,et al.SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia[J].J Clin Invest,2021,131(16):e141083.[20]Wang QW,Sun LH,Zhang Y,et al.MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated,macrophages-mediated immunosuppression in primary glioblastomas[J].J Immunother Cancer,2021,9(10):e002451.[21]Moore JA,Mistry JJ,Hellmich C,et al.LC3-associated phagocytosis in bone marrow macrophages suppresses acute myeloid leukemia progression through STING activation[J].J Clin Invest,2022,132(5):e153157.[22]Brauneck F,Fischer B,Witt M,et al.TIGIT blockade repolarizes AML-associated TIGIT M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis[J].J Immunother Cancer,2022,10(12):e004794.
相似文献/References:
[1]白 雪,朱海波,邓 琦,等.PD-L1在急性髓系白血病中的表达及临床意义[J].医学信息,2019,32(06):79.[doi:10.3969/j.issn.1006-1959.2019.06.025]
BAI Xue,ZHU Hai-bo,DENG Qi,et al.Expression and Clinical Significance of PD-L1 in Acute Myeloid Leukemia[J].Journal of Medical Information,2019,32(07):79.[doi:10.3969/j.issn.1006-1959.2019.06.025]
[2]曹忠钰,白家英,李 泽.以面瘫为首发症状的小儿急性髓系白血病1例并文献复习[J].医学信息,2020,33(03):190.[doi:10.3969/j.issn.1006-1959.2019.17.065]
[3]曾雪娇,谢仁古丽·阿力木,庞楠楠,等.急性白血病预后相关基因突变的研究[J].医学信息,2021,34(20):41.[doi:10.3969/j.issn.1006-1959.2021.20.010]
ZENG Xue-jiao,XIERENGULI Alimu,PANG Nan-nan,et al.Research on Prognosis-related Gene Mutations of Acute Leukemia[J].Journal of Medical Information,2021,34(07):41.[doi:10.3969/j.issn.1006-1959.2021.20.010]
[4]赵崇山,王宁方.脾脏硬度联合流式细胞术在急性髓系白血病微小残留病监测中的意义[J].医学信息,2022,35(05):121.[doi:10.3969/j.issn.1006-1959.2022.05.031]
ZHAO Chong-shan,WANG Ning-fang.The Significance of Spleen Stiffness Measurement Combine with Flow Cytometry in Acute Myeloid Leukemia Minimal Residual Disease[J].Journal of Medical Information,2022,35(07):121.[doi:10.3969/j.issn.1006-1959.2022.05.031]